Send us a Message
Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   
Search RGD Grant Resources Citing RGD About Us Contact Us
Genes Variants Community Projects QTLs Strains Markers Genome Information Ontologies Cell Lines References Download Submit Data
OntoMate (Literature Search) JBrowse (Genome Browser) Synteny Browser (VCMap) Variant Visualizer Multi-Ontology Enrichment (MOET) Gene-Ortholog Location Finder (GOLF) InterViewer (Protein-Protein Interactions) PhenoMiner (Quatitative Phenotypes) Gene Annotator OLGA (Gene List Generator) AllianceMine GViewer (Genome Viewer)
Aging & Age-Related Disease Cancer & Neoplastic Disease Cardiovascular Disease Coronavirus Disease Developmental Disease Diabetes Hematologic Disease Immune & Inflammatory Disease Infectious Disease Liver Disease Neurological Disease Obesity & Metabolic Syndrome Renal Disease Respiratory Disease Sensory Organ Disease
Find Models Genetic Models Autism Models Rat PhenoMiner (Quantitative Phenotypes) Chinchilla PhenoMiner Expected Ranges (Quantitative Phenotype) PhenoMiner Term Comparison Hybrid Rat Diversity Panel Phenotypes Phenotypes in Other Animal Models Animal Husbandry Strain Medical Records Phylogenetics Strain Availability Calendar Rats 101 Submissions Photo Archive
Pathways
Rat Community Forum Directory of Rat Laboratories Video Tutorials News RGD Publications RGD Presentations Archive Nomenclature Guidelines Resource Links Laboratory Resources Employment Resources
Advanced Search (OLGA)

CHEBI ONTOLOGY - ANNOTATIONS

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
Term:piperidinecarboxamide
go back to main search page
Accession:CHEBI:48592 term browser browse the term
Synonyms:related_synonym: piperidinecarboxamides


show annotations for term's descendants           Sort by:
(S)-ropivacaine term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Aifm1 apoptosis inducing factor, mitochondria associated 1 increases expression ISO Ropivacaine results in increased expression of AIFM1 protein CTD PMID:28079261 NCBI chr  X:127,650,223...127,689,356
Ensembl chr  X:127,650,226...127,689,256 		JBrowse link
G Akt1 AKT serine/threonine kinase 1 decreases phosphorylation ISO Ropivacaine results in decreased phosphorylation of AKT1 protein CTD PMID:36124980 PMID:36193553 NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921 		JBrowse link
G Bax BCL2 associated X, apoptosis regulator increases expression
multiple interactions		 EXP
ISO		 Ropivacaine results in increased expression of BAX mRNA; Ropivacaine results in increased expression of BAX protein
pifithrin inhibits the reaction [Ropivacaine results in increased expression of BAX mRNA]; pifithrin inhibits the reaction [Ropivacaine results in increased expression of BAX protein]
Ropivacaine promotes the reaction [Cisplatin results in increased expression of BAX protein]		 CTD PMID:34091999 PMID:36193553 PMID:39053794 NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368 		JBrowse link
G Bcl2 BCL2, apoptosis regulator decreases response to substance
multiple interactions
decreases expression		 ISO
EXP		 BCL2 protein results in decreased susceptibility to Ropivacaine
BCL2 protein inhibits the reaction [Ropivacaine results in increased cleavage of CASP3 protein]; BCL2 protein inhibits the reaction [Ropivacaine results in increased cleavage of PARP1 protein]; Ropivacaine promotes the reaction [Cisplatin results in decreased expression of BCL2 protein]
pifithrin inhibits the reaction [Ropivacaine results in decreased expression of BCL2 mRNA]; pifithrin inhibits the reaction [Ropivacaine results in decreased expression of BCL2 protein]
Ropivacaine results in decreased expression of BCL2 mRNA; Ropivacaine results in decreased expression of BCL2 protein		 CTD PMID:15538973 PMID:34091999 PMID:36193553 PMID:39053794 NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743 		JBrowse link
G Becn1 beclin 1 increases expression
multiple interactions		 ISO Ropivacaine results in increased expression of BECN1 protein
Ropivacaine inhibits the reaction [3-methyladenine results in decreased expression of BECN1 protein]		 CTD PMID:36193553 NCBI chr10:86,231,387...86,246,742
Ensembl chr10:86,231,388...86,246,742 		JBrowse link
G Casp1 caspase 1 multiple interactions
increases cleavage		 ISO Dexmedetomidine inhibits the reaction [Ropivacaine results in increased cleavage of CASP1 protein]; NFE2L2 protein promotes the reaction [Dexmedetomidine inhibits the reaction [Ropivacaine results in increased cleavage of CASP1 protein]]; zinc protoporphyrin inhibits the reaction [Dexmedetomidine inhibits the reaction [Ropivacaine results in increased cleavage of CASP1 protein]] CTD PMID:36858639 NCBI chr 8:2,587,812...2,597,403
Ensembl chr 8:2,587,831...2,597,383 		JBrowse link
G Casp3 caspase 3 increases cleavage
decreases expression
multiple interactions
increases expression		 ISO
EXP		 Ropivacaine results in increased cleavage of CASP3 protein
Ropivacaine results in decreased expression of CASP3 protein
BCL2 protein inhibits the reaction [Ropivacaine results in increased cleavage of CASP3 protein]; CLU protein inhibits the reaction [Ropivacaine results in increased expression of CASP3 protein]
Ropivacaine results in increased expression of CASP3 mRNA
pifithrin inhibits the reaction [Ropivacaine results in increased cleavage of CASP3 protein]; pifithrin inhibits the reaction [Ropivacaine results in increased expression of CASP3 mRNA]		 CTD PMID:15538973 PMID:20194319 PMID:34091999 PMID:36193553 NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648 		JBrowse link
G Casp9 caspase 9 decreases expression ISO Ropivacaine results in decreased expression of CASP9 protein CTD PMID:20194319 NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626 		JBrowse link
G Clu clusterin multiple interactions
decreases response to substance
decreases expression		 ISO CLU protein inhibits the reaction [Ropivacaine results in increased cleavage of PARP1 protein]; CLU protein inhibits the reaction [Ropivacaine results in increased expression of CASP3 protein]
CLU protein results in decreased susceptibility to Ropivacaine
Ropivacaine results in decreased expression of CLU protein		 CTD PMID:15538973 NCBI chr15:40,161,068...40,200,315
Ensembl chr15:40,174,617...40,200,315 		JBrowse link
G Gpx4 glutathione peroxidase 4 decreases expression
multiple interactions		 ISO Ropivacaine results in decreased expression of GPX4 protein
[Ropivacaine results in increased susceptibility to Cisplatin] which results in decreased expression of GPX4 protein; Ropivacaine promotes the reaction [Cisplatin results in decreased expression of GPX4 protein]; SIRT1 protein affects the reaction [[Ropivacaine results in increased susceptibility to Cisplatin] which results in decreased expression of GPX4 protein]		 CTD PMID:36124980 PMID:39053794 NCBI chr 7:9,650,186...9,652,982
Ensembl chr 7:9,650,185...9,652,982 		JBrowse link
G Gsdmd gasdermin D increases cleavage
multiple interactions		 ISO Ropivacaine results in increased cleavage of GSDMD protein
Dexmedetomidine inhibits the reaction [Ropivacaine results in increased cleavage of GSDMD protein]; NFE2L2 protein promotes the reaction [Dexmedetomidine inhibits the reaction [Ropivacaine results in increased cleavage of GSDMD protein]]; zinc protoporphyrin inhibits the reaction [Dexmedetomidine inhibits the reaction [Ropivacaine results in increased cleavage of GSDMD protein]]		 CTD PMID:36858639 NCBI chr 7:107,542,489...107,547,051
Ensembl chr 7:107,542,083...107,547,055 		JBrowse link
G Hmox1 heme oxygenase 1 increases expression
multiple interactions		 ISO Ropivacaine results in increased expression of HMOX1 protein
Dexmedetomidine promotes the reaction [Ropivacaine results in increased expression of HMOX1 protein]; NFE2L2 protein promotes the reaction [Dexmedetomidine promotes the reaction [Ropivacaine results in increased expression of HMOX1 protein]]; zinc protoporphyrin inhibits the reaction [Dexmedetomidine promotes the reaction [Ropivacaine results in increased expression of HMOX1 protein]]		 CTD PMID:36858639 NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079 		JBrowse link
G Hoxd10 homeo box D10 multiple interactions
increases expression		 ISO [Sorafenib co-treated with Ropivacaine] results in increased expression of HOXD10 protein; MIR224 inhibits the reaction [[Sorafenib co-treated with Ropivacaine] results in increased expression of HOXD10 protein]
Ropivacaine results in increased expression of HOXD10 protein		 CTD PMID:38197552 NCBI chr 3:59,594,516...59,597,725
Ensembl chr 3:59,594,516...59,597,725 		JBrowse link
G Hrh1 histamine receptor H 1 affects binding ISO HRH1 protein binds to Ropivacaine CTD PMID:32061592 NCBI chr 4:147,564,963...147,649,353
Ensembl chr 4:147,645,995...147,647,455 		JBrowse link
G Il18 interleukin 18 increases expression
multiple interactions		 ISO Ropivacaine results in increased expression of IL18 protein
Dexmedetomidine inhibits the reaction [Ropivacaine results in increased expression of IL18 protein]; NFE2L2 protein promotes the reaction [Dexmedetomidine inhibits the reaction [Ropivacaine results in increased expression of IL18 protein]]; zinc protoporphyrin inhibits the reaction [Dexmedetomidine inhibits the reaction [Ropivacaine results in increased expression of IL18 protein]]		 CTD PMID:36858639 NCBI chr 8:50,904,630...50,932,887
Ensembl chr 8:50,906,960...50,932,887 		JBrowse link
G Il1b interleukin 1 beta multiple interactions
increases expression		 ISO Dexmedetomidine inhibits the reaction [Ropivacaine results in increased expression of IL1B protein]; NFE2L2 protein promotes the reaction [Dexmedetomidine inhibits the reaction [Ropivacaine results in increased expression of IL1B protein]]; zinc protoporphyrin inhibits the reaction [Dexmedetomidine inhibits the reaction [Ropivacaine results in increased expression of IL1B protein]] CTD PMID:36858639 NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415 		JBrowse link
G Itgam integrin subunit alpha M multiple interactions ISO Ropivacaine inhibits the reaction [TNF protein results in increased expression of [ITGAM protein binds to ITGB2 protein]] CTD PMID:9336308 NCBI chr 1:182,659,047...182,709,501
Ensembl chr 1:182,659,000...182,709,503 		JBrowse link
G Itgb2 integrin subunit beta 2 multiple interactions ISO Ropivacaine inhibits the reaction [TNF protein results in increased expression of [ITGAM protein binds to ITGB2 protein]] CTD PMID:9336308 NCBI chr20:11,061,394...11,097,656
Ensembl chr20:11,061,430...11,097,600 		JBrowse link
G Kcne1 potassium voltage-gated channel subfamily E regulatory subunit 1 multiple interactions ISO Ropivacaine results in decreased activity of [KCNQ1 protein binds to KCNE1 protein] CTD PMID:16931984 NCBI chr11:31,580,951...31,594,116
Ensembl chr11:31,580,742...31,593,901 		JBrowse link
G Kcnq1 potassium voltage-gated channel subfamily Q member 1 decreases activity
multiple interactions		 ISO Ropivacaine results in decreased activity of KCNQ1 protein
Ropivacaine results in decreased activity of [KCNQ1 protein binds to KCNE1 protein]		 CTD PMID:16931984 NCBI chr 1:198,291,711...198,624,683
Ensembl chr 1:198,291,766...198,624,669 		JBrowse link
G Keap1 Kelch-like ECH-associated protein 1 multiple interactions ISO [Ropivacaine results in increased susceptibility to Cisplatin] which results in increased expression of KEAP1 protein; SIRT1 protein affects the reaction [[Ropivacaine results in increased susceptibility to Cisplatin] which results in increased expression of KEAP1 protein] CTD PMID:39053794 NCBI chr 8:19,768,375...19,777,862
Ensembl chr 8:19,768,375...19,777,862 		JBrowse link
G Ldha lactate dehydrogenase A increases expression
multiple interactions		 ISO Ropivacaine results in increased expression of LDHA protein
Dexmedetomidine inhibits the reaction [Ropivacaine results in increased expression of LDHA protein]; NFE2L2 protein promotes the reaction [Dexmedetomidine inhibits the reaction [Ropivacaine results in increased expression of LDHA protein]]; zinc protoporphyrin inhibits the reaction [Dexmedetomidine inhibits the reaction [Ropivacaine results in increased expression of LDHA protein]]		 CTD PMID:36858639 NCBI chr 1:97,371,823...97,381,247
Ensembl chr 1:97,366,021...97,433,472 		JBrowse link
G Mir224 microRNA 224 multiple interactions ISO MIR224 inhibits the reaction [[Sorafenib co-treated with Ropivacaine] results in increased expression of HOXD10 protein]; Ropivacaine promotes the reaction [Sorafenib results in decreased expression of MIR224 mRNA] CTD PMID:38197552 NCBI chr  X:150,065,088...150,065,169
Ensembl chr  X:150,065,088...150,065,169 		JBrowse link
G Mki67 marker of proliferation Ki-67 decreases expression ISO Ropivacaine results in decreased expression of MKI67 protein CTD PMID:36193553 NCBI chr 1:190,496,319...190,522,983
Ensembl chr 1:190,496,319...190,522,762 		JBrowse link
G Mmp9 matrix metallopeptidase 9 multiple interactions ISO [Ropivacaine results in increased susceptibility to Cisplatin] which results in decreased expression of MMP9 protein; Ropivacaine promotes the reaction [Cisplatin results in decreased expression of MMP9 protein] CTD PMID:39053794 NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120 		JBrowse link
G Mtor mechanistic target of rapamycin kinase decreases phosphorylation ISO Ropivacaine results in decreased phosphorylation of MTOR protein CTD PMID:36124980 PMID:36193553 NCBI chr 5:158,884,856...158,994,311
Ensembl chr 5:158,884,804...158,994,311 		JBrowse link
G Nanog Nanog homeobox decreases expression ISO Ropivacaine results in decreased expression of NANOG protein CTD PMID:36124980 NCBI chr 4:155,943,737...155,951,116
Ensembl chr 4:155,943,737...155,951,116 		JBrowse link
G Nfe2l2 NFE2 like bZIP transcription factor 2 multiple interactions ISO [Ropivacaine results in increased susceptibility to Cisplatin] which results in decreased expression of NFE2L2 protein; Dexmedetomidine promotes the reaction [Ropivacaine results in increased expression of and results in increased localization of NFE2L2 protein]; NFE2L2 protein promotes the reaction [Dexmedetomidine inhibits the reaction [Ropivacaine results in increased cleavage of CASP1 protein]]; NFE2L2 protein promotes the reaction [Dexmedetomidine inhibits the reaction [Ropivacaine results in increased cleavage of GSDMD protein]]; NFE2L2 protein promotes the reaction [Dexmedetomidine inhibits the reaction [Ropivacaine results in increased expression of IL18 protein]]; NFE2L2 protein promotes the reaction [Dexmedetomidine inhibits the reaction [Ropivacaine results in increased expression of IL1B protein]]; NFE2L2 protein promotes the reaction [Dexmedetomidine inhibits the reaction [Ropivacaine results in increased expression of LDHA protein]]; NFE2L2 protein promotes the reaction [Dexmedetomidine inhibits the reaction [Ropivacaine results in increased expression of NLRP3 protein]]; NFE2L2 protein promotes the reaction [Dexmedetomidine promotes the reaction [Ropivacaine results in increased expression of HMOX1 protein]]; Ropivacaine promotes the reaction [Cisplatin results in decreased expression of NFE2L2 protein]; Ropivacaine results in increased expression of and results in increased localization of NFE2L2 protein; SIRT1 protein affects the reaction [[Ropivacaine results in increased susceptibility to Cisplatin] which results in decreased expression of NFE2L2 protein] CTD PMID:36858639 PMID:39053794 NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737 		JBrowse link
G Nlrp3 NLR family, pyrin domain containing 3 increases expression
multiple interactions		 ISO Ropivacaine results in increased expression of NLRP3 protein
Dexmedetomidine inhibits the reaction [Ropivacaine results in increased expression of NLRP3 protein]; NFE2L2 protein promotes the reaction [Dexmedetomidine inhibits the reaction [Ropivacaine results in increased expression of NLRP3 protein]]		 CTD PMID:36858639 NCBI chr10:44,326,770...44,353,814
Ensembl chr10:44,328,566...44,352,811 		JBrowse link
G Parp1 poly (ADP-ribose) polymerase 1 increases cleavage
multiple interactions
increases expression		 ISO Ropivacaine results in increased cleavage of PARP1 protein
BCL2 protein inhibits the reaction [Ropivacaine results in increased cleavage of PARP1 protein]; CLU protein inhibits the reaction [Ropivacaine results in increased cleavage of PARP1 protein]
Ropivacaine results in increased expression of PARP1 protein		 CTD PMID:15538973 PMID:28079261 NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404 		JBrowse link
G Pik3r1 phosphoinositide-3-kinase regulatory subunit 1 decreases phosphorylation ISO Ropivacaine results in decreased phosphorylation of PIK3R1 protein CTD PMID:36124980 NCBI chr 2:32,878,942...32,963,668
Ensembl chr 2:32,882,032...32,963,631 		JBrowse link
G Pou5f1 POU class 5 homeobox 1 decreases expression ISO Ropivacaine results in decreased expression of POU5F1 protein CTD PMID:36124980 NCBI chr20:3,223,128...3,227,891
Ensembl chr20:3,223,129...3,227,891 		JBrowse link
G Sell selectin L multiple interactions ISO Ropivacaine inhibits the reaction [TNF protein results in increased cleavage of SELL protein] CTD PMID:9336308 NCBI chr13:76,416,969...76,436,444
Ensembl chr13:76,416,915...76,436,456 		JBrowse link
G Sirt1 sirtuin 1 multiple interactions ISO [Ropivacaine results in increased susceptibility to Cisplatin] which results in decreased expression of SIRT1 protein; Ropivacaine promotes the reaction [Cisplatin results in decreased expression of SIRT1 protein]; SIRT1 protein affects the reaction [[Ropivacaine results in increased susceptibility to Cisplatin] which results in decreased expression of GPX4 protein]; SIRT1 protein affects the reaction [[Ropivacaine results in increased susceptibility to Cisplatin] which results in decreased expression of NFE2L2 protein]; SIRT1 protein affects the reaction [[Ropivacaine results in increased susceptibility to Cisplatin] which results in decreased expression of SLC7A11 protein]; SIRT1 protein affects the reaction [[Ropivacaine results in increased susceptibility to Cisplatin] which results in increased expression of KEAP1 protein] CTD PMID:39053794 NCBI chr20:25,307,225...25,329,273
Ensembl chr20:25,306,917...25,329,260 		JBrowse link
G Slc25a29 solute carrier family 25 member 29 decreases activity
multiple interactions		 EXP Ropivacaine results in decreased activity of SLC25A29 protein
Emulsions inhibits the reaction [Ropivacaine results in decreased activity of SLC25A29 protein]		 CTD PMID:35135371 NCBI chr 6:127,742,027...127,752,915
Ensembl chr 6:127,742,033...127,752,940 		JBrowse link
G Slc7a11 solute carrier family 7 member 11 decreases expression
multiple interactions		 ISO Ropivacaine results in decreased expression of SLC7A11 protein
[Ropivacaine results in increased susceptibility to Cisplatin] which results in decreased expression of SLC7A11 protein; Ropivacaine promotes the reaction [Cisplatin results in decreased expression of SLC7A11 protein]; SIRT1 protein affects the reaction [[Ropivacaine results in increased susceptibility to Cisplatin] which results in decreased expression of SLC7A11 protein]		 CTD PMID:36124980 PMID:39053794 NCBI chr 2:134,382,002...134,517,622
Ensembl chr 2:133,963,107...134,517,536 		JBrowse link
G Sqstm1 sequestosome 1 multiple interactions
decreases expression		 ISO Ropivacaine inhibits the reaction [3-methyladenine results in increased expression of SQSTM1 protein]
Ropivacaine results in decreased expression of SQSTM1 protein		 CTD PMID:36193553 NCBI chr10:34,525,517...34,536,670
Ensembl chr10:34,525,519...34,536,673 		JBrowse link
G Sult1a1 sulfotransferase family 1A member 1 increases sulfation ISO SULT1A1 protein results in increased sulfation of Ropivacaine metabolite CTD PMID:10460806 NCBI chr 1:181,272,022...181,276,750
Ensembl chr 1:181,272,023...181,275,562 		JBrowse link
G Sult1e1 sulfotransferase family 1E member 1 increases sulfation ISO SULT1E1 protein results in increased sulfation of Ropivacaine metabolite CTD PMID:10460806 NCBI chr14:20,422,324...20,439,562
Ensembl chr14:20,422,324...20,439,275 		JBrowse link
G Tnf tumor necrosis factor multiple interactions ISO Ropivacaine inhibits the reaction [TNF protein results in increased cleavage of SELL protein]; Ropivacaine inhibits the reaction [TNF protein results in increased expression of [ITGAM protein binds to ITGB2 protein]] CTD PMID:9336308 NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629 		JBrowse link
G Tp53 tumor protein p53 multiple interactions
increases expression		 EXP pifithrin inhibits the reaction [Ropivacaine results in increased expression of TP53 mRNA]; pifithrin inhibits the reaction [Ropivacaine results in increased expression of TP53 protein]
Ropivacaine results in increased expression of TP53 mRNA; Ropivacaine results in increased expression of TP53 protein		 CTD PMID:34091999 NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524 		JBrowse link
G Vegfa vascular endothelial growth factor A decreases expression ISO Ropivacaine results in decreased expression of VEGFA protein CTD PMID:36193553 NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641 		JBrowse link
bupivacaine term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Bax BCL2 associated X, apoptosis regulator increases expression
multiple interactions		 ISO Bupivacaine results in increased expression of BAX protein
8-dibenzothiophen-4-yl-2-morpholin-4-yl-chromen-4-one promotes the reaction [[Glucose co-treated with Bupivacaine] results in increased expression of BAX protein]; [Glucose co-treated with Bupivacaine] results in increased expression of BAX protein		 CTD PMID:31672611 NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368 		JBrowse link
G Bcl2 BCL2, apoptosis regulator decreases expression
multiple interactions		 ISO Bupivacaine results in decreased expression of BCL2 protein
8-dibenzothiophen-4-yl-2-morpholin-4-yl-chromen-4-one promotes the reaction [[Glucose co-treated with Bupivacaine] results in decreased expression of BCL2 protein]; [Glucose co-treated with Bupivacaine] results in decreased expression of BCL2 protein; HSPA12A protein inhibits the reaction [Bupivacaine results in decreased expression of BCL2 protein]		 CTD PMID:31672611 PMID:34793778 NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743 		JBrowse link
G Bdnf brain-derived neurotrophic factor multiple interactions
decreases expression		 ISO MIR497 mRNA affects the reaction [Bupivacaine results in decreased expression of BDNF mRNA]; MIR497 mRNA inhibits the reaction [SNHG12 inhibits the reaction [Bupivacaine results in decreased expression of BDNF mRNA]]; NLRX1 protein affects the reaction [MIR497 mRNA affects the reaction [Bupivacaine results in decreased expression of BDNF mRNA]]; SNHG12 inhibits the reaction [Bupivacaine results in decreased expression of BDNF mRNA] CTD PMID:35410500 NCBI chr 3:96,165,042...96,215,621
Ensembl chr 3:96,165,042...96,215,615 		JBrowse link
G Casp3 caspase 3 decreases expression
increases cleavage
multiple interactions
increases activity		 ISO
EXP		 Bupivacaine results in decreased expression of CASP3 protein
Bupivacaine results in increased cleavage of CASP3 protein
MCL1 protein promotes the reaction [notoginsenoside R1 inhibits the reaction [Bupivacaine results in increased cleavage of CASP3 protein]]; notoginsenoside R1 inhibits the reaction [Bupivacaine results in increased cleavage of CASP3 protein]
Bupivacaine results in increased activity of CASP3 protein		 CTD PMID:16109997 PMID:20194319 PMID:38316350 NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648 		JBrowse link
G Casp9 caspase 9 decreases expression
multiple interactions
increases cleavage		 ISO Bupivacaine results in decreased expression of CASP9 protein
MCL1 protein promotes the reaction [notoginsenoside R1 inhibits the reaction [Bupivacaine results in increased cleavage of CASP9 protein]]; notoginsenoside R1 inhibits the reaction [Bupivacaine results in increased cleavage of CASP9 protein]		 CTD PMID:20194319 PMID:38316350 NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626 		JBrowse link
G Cs citrate synthase decreases activity EXP Bupivacaine results in decreased activity of CS protein CTD PMID:20645041 NCBI chr 7:758,074...791,421
Ensembl chr 7:758,345...791,421 		JBrowse link
G Cyp3a9 cytochrome P450, family 3, subfamily a, polypeptide 9 multiple interactions EXP [Bupivacaine co-treated with Tetrodotoxin co-treated with Dexamethasone] results in decreased expression of CYP3A9 mRNA CTD PMID:22341215 NCBI chr12:16,806,222...16,846,428
Ensembl chr12:16,806,207...16,846,422 		JBrowse link
G Dnm1l dynamin 1-like decreases expression
multiple interactions		 ISO Bupivacaine results in decreased expression of DNM1L protein
HSPA12A protein inhibits the reaction [Bupivacaine results in decreased expression of DNM1L protein]		 CTD PMID:34793778 NCBI chr11:84,581,216...84,632,382
Ensembl chr11:84,581,216...84,631,482 		JBrowse link
G Entpd4 ectonucleoside triphosphate diphosphohydrolase 4 multiple interactions EXP [Bupivacaine co-treated with Tetrodotoxin co-treated with Dexamethasone] results in decreased expression of ENTPD4 mRNA CTD PMID:22341215 NCBI chr15:44,630,878...44,658,654
Ensembl chr15:44,630,873...44,658,706 		JBrowse link
G H2ax H2A.X variant histone multiple interactions
increases expression		 ISO Glucose promotes the reaction [Bupivacaine results in increased expression of H2AX protein] CTD PMID:31672611 NCBI chr 8:44,671,907...44,673,262
Ensembl chr 8:44,671,786...44,673,239
Ensembl chr 4:44,671,786...44,673,239 		JBrowse link
G Hpgds hematopoietic prostaglandin D synthase increases expression ISO Bupivacaine results in increased expression of HPGDS mRNA; Bupivacaine results in increased expression of HPGDS protein CTD PMID:19359520 NCBI chr 4:94,368,426...94,397,931
Ensembl chr 4:94,373,342...94,397,883 		JBrowse link
G Hrh1 histamine receptor H 1 affects binding ISO HRH1 protein binds to Bupivacaine CTD PMID:32061592 NCBI chr 4:147,564,963...147,649,353
Ensembl chr 4:147,645,995...147,647,455 		JBrowse link
G Hspa12a heat shock protein family A (Hsp70) member 12A decreases expression
multiple interactions		 ISO Bupivacaine results in decreased expression of HSPA12A protein
HSPA12A protein inhibits the reaction [Bupivacaine results in decreased expression of BCL2 protein]; HSPA12A protein inhibits the reaction [Bupivacaine results in decreased expression of DNM1L protein]; HSPA12A protein inhibits the reaction [Bupivacaine results in decreased expression of MFN1 protein]; HSPA12A protein inhibits the reaction [Bupivacaine results in decreased expression of PINK1 protein]; HSPA12A protein inhibits the reaction [Bupivacaine results in decreased expression of PPARGC1A protein]; HSPA12A protein inhibits the reaction [Bupivacaine results in decreased expression of PRKN protein]; HSPA12A protein inhibits the reaction [Bupivacaine results in decreased expression of SLC2A1 protein]; HSPA12A protein inhibits the reaction [Bupivacaine results in decreased expression of SLC2A4 protein]; HSPA12A protein inhibits the reaction [Bupivacaine results in decreased expression of TOMM20 protein]		 CTD PMID:34793778 NCBI chr 1:257,935,642...258,096,602
Ensembl chr 1:257,935,644...258,096,846 		JBrowse link
G Itgam integrin subunit alpha M increases expression
multiple interactions		 ISO Bupivacaine results in increased expression of ITGAM mRNA
4-benzhydryloxy-1-(3-(1H-tetrazol-5-yl-)-propyl)piperidine inhibits the reaction [Bupivacaine results in increased expression of ITGAM mRNA]		 CTD PMID:19359520 NCBI chr 1:182,659,047...182,709,501
Ensembl chr 1:182,659,000...182,709,503 		JBrowse link
G Kcne1 potassium voltage-gated channel subfamily E regulatory subunit 1 multiple interactions ISO Bupivacaine results in decreased activity of [KCNQ1 protein binds to KCNE1 protein]; KCNE1 protein inhibits the reaction [KCNQ1 protein mutant form results in increased susceptibility to Bupivacaine] CTD PMID:16931984 NCBI chr11:31,580,951...31,594,116
Ensembl chr11:31,580,742...31,593,901 		JBrowse link
G Kcnk9 potassium two pore domain channel subfamily K member 9 multiple interactions ISO Bupivacaine inhibits the reaction [KCNK9 protein results in increased transport of Potassium] CTD PMID:11249964 NCBI chr 7:104,429,186...104,473,924
Ensembl chr 7:104,437,934...104,473,175 		JBrowse link
G Kcnn2 potassium calcium-activated channel subfamily N member 2 affects response to substance
decreases activity		 ISO KCNN2 protein affects the susceptibility to Bupivacaine
Bupivacaine results in decreased activity of KCNN2 protein		 CTD PMID:32909839 PMID:33887967 NCBI chr18:37,817,966...38,258,347
Ensembl chr18:37,817,957...38,258,347 		JBrowse link
G Kcnq1 potassium voltage-gated channel subfamily Q member 1 multiple interactions
increases response to substance
decreases activity		 ISO Bupivacaine results in decreased activity of [KCNQ1 protein binds to KCNE1 protein]; KCNE1 protein inhibits the reaction [KCNQ1 protein mutant form results in increased susceptibility to Bupivacaine]
Bupivacaine results in decreased activity of KCNQ1 protein		 CTD PMID:16931984 NCBI chr 1:198,291,711...198,624,683
Ensembl chr 1:198,291,766...198,624,669 		JBrowse link
G Ldha lactate dehydrogenase A increases secretion
multiple interactions		 ISO Bupivacaine results in increased secretion of LDHA protein
notoginsenoside R1 inhibits the reaction [Bupivacaine results in increased secretion of LDHA protein]		 CTD PMID:38316350 NCBI chr 1:97,371,823...97,381,247
Ensembl chr 1:97,366,021...97,433,472 		JBrowse link
G Mapk1 mitogen activated protein kinase 1 increases phosphorylation
multiple interactions		 ISO Bupivacaine results in increased phosphorylation of MAPK1 protein
Glucose promotes the reaction [Bupivacaine results in increased phosphorylation of MAPK1 protein]		 CTD PMID:34060177 NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616 		JBrowse link
G Mapk3 mitogen activated protein kinase 3 increases phosphorylation
multiple interactions		 ISO Bupivacaine results in increased phosphorylation of MAPK3 protein
Glucose promotes the reaction [Bupivacaine results in increased phosphorylation of MAPK3 protein]		 CTD PMID:34060177 NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863 		JBrowse link
G Mcl1 MCL1 apoptosis regulator, BCL2 family member decreases expression
multiple interactions		 ISO Bupivacaine results in decreased expression of MCL1 protein
MCL1 protein promotes the reaction [notoginsenoside R1 inhibits the reaction [Bupivacaine results in increased cleavage of CASP3 protein]]; MCL1 protein promotes the reaction [notoginsenoside R1 inhibits the reaction [Bupivacaine results in increased cleavage of CASP9 protein]]		 CTD PMID:38316350 NCBI chr 2:183,219,137...183,235,676
Ensembl chr 2:183,219,220...183,222,303 		JBrowse link
G Mfn1 mitofusin 1 decreases expression
multiple interactions		 ISO Bupivacaine results in decreased expression of MFN1 protein
HSPA12A protein inhibits the reaction [Bupivacaine results in decreased expression of MFN1 protein]		 CTD PMID:34793778 NCBI chr 2:115,313,380...115,359,651
Ensembl chr 2:115,313,401...115,359,640 		JBrowse link
G Mir497 microRNA 497 multiple interactions
increases expression		 ISO MIR497 mRNA affects the reaction [Bupivacaine results in decreased expression of BDNF mRNA]; MIR497 mRNA inhibits the reaction [SNHG12 inhibits the reaction [Bupivacaine results in decreased expression of BDNF mRNA]]; MIR497 mRNA promotes the reaction [Bupivacaine results in decreased expression of NLRX1 mRNA]; NLRX1 protein affects the reaction [MIR497 mRNA affects the reaction [Bupivacaine results in decreased expression of BDNF mRNA]]; SNHG12 inhibits the reaction [Bupivacaine results in increased expression of MIR497 mRNA] CTD PMID:35410500 NCBI chr10:54,951,514...54,951,582
Ensembl chr10:54,951,505...54,951,584 		JBrowse link
G Myf5 myogenic factor 5 decreases expression EXP Bupivacaine results in decreased expression of MYF5 protein CTD PMID:10434046 NCBI chr 7:42,802,946...42,806,177
Ensembl chr 7:42,802,946...42,806,177 		JBrowse link
G Myod1 myogenic differentiation 1 decreases expression EXP Bupivacaine results in decreased expression of MYOD1 protein CTD PMID:10434046 NCBI chr 1:96,884,864...96,887,574
Ensembl chr 1:96,884,948...96,887,554 		JBrowse link
G Myog myogenin decreases expression EXP Bupivacaine results in decreased expression of MYOG protein CTD PMID:10434046 NCBI chr13:45,745,455...45,748,044
Ensembl chr13:45,745,436...45,748,039 		JBrowse link
G Nlrx1 NLR family member X1 multiple interactions
decreases expression		 ISO MIR497 mRNA promotes the reaction [Bupivacaine results in decreased expression of NLRX1 mRNA]; NLRX1 protein affects the reaction [MIR497 mRNA affects the reaction [Bupivacaine results in decreased expression of BDNF mRNA]]; SNHG12 inhibits the reaction [Bupivacaine results in decreased expression of NLRX1 mRNA] CTD PMID:35410500 NCBI chr 8:44,588,476...44,606,678
Ensembl chr 8:44,590,048...44,606,484 		JBrowse link
G Pink1 PTEN induced kinase 1 decreases expression
multiple interactions		 ISO Bupivacaine results in decreased expression of PINK1 protein
HSPA12A protein inhibits the reaction [Bupivacaine results in decreased expression of PINK1 protein]		 CTD PMID:34793778 NCBI chr 5:150,530,523...150,542,635
Ensembl chr 5:150,530,523...150,542,635 		JBrowse link
G Ppargc1a PPARG coactivator 1 alpha increases expression
multiple interactions
decreases expression		 ISO Bupivacaine results in increased expression of PPARGC1A mRNA
HSPA12A protein inhibits the reaction [Bupivacaine results in decreased expression of PPARGC1A protein]		 CTD PMID:34793778 NCBI chr14:58,860,752...59,516,525
Ensembl chr14:58,861,144...59,512,656 		JBrowse link
G Prkcb protein kinase C, beta multiple interactions EXP [Bupivacaine co-treated with Tetrodotoxin co-treated with Dexamethasone] results in decreased expression of PRKCB mRNA CTD PMID:22341215 NCBI chr 1:176,832,173...177,163,539
Ensembl chr 1:176,832,226...177,163,536 		JBrowse link
G Prkn parkin RBR E3 ubiquitin protein ligase decreases expression
multiple interactions		 ISO Bupivacaine results in decreased expression of PRKN protein
HSPA12A protein inhibits the reaction [Bupivacaine results in decreased expression of PRKN protein]		 CTD PMID:34793778 NCBI chr 1:48,688,651...49,882,520
Ensembl chr 1:48,690,556...49,882,555 		JBrowse link
G Ptgdr prostaglandin D2 receptor affects expression ISO Bupivacaine affects the expression of PTGDR mRNA CTD PMID:19359520 NCBI chr15:17,360,304...17,367,679
Ensembl chr15:17,360,304...17,367,679 		JBrowse link
G Ptgs1 prostaglandin-endoperoxide synthase 1 increases expression ISO Bupivacaine results in increased expression of PTGS1 mRNA CTD PMID:18165598 NCBI chr 3:19,584,015...19,605,589
Ensembl chr 3:19,584,015...19,605,586 		JBrowse link
G Ptgs2 prostaglandin-endoperoxide synthase 2 increases expression
multiple interactions		 ISO Bupivacaine results in increased expression of PTGS2 mRNA
[Bupivacaine results in increased expression of PTGS2] which results in increased abundance of Dinoprostone		 CTD PMID:18165598 NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188 		JBrowse link
G Slc25a29 solute carrier family 25 member 29 multiple interactions
decreases activity		 EXP Emulsions inhibits the reaction [Bupivacaine results in decreased activity of SLC25A29 protein] CTD PMID:35135371 NCBI chr 6:127,742,027...127,752,915
Ensembl chr 6:127,742,033...127,752,940 		JBrowse link
G Slc2a1 solute carrier family 2 member 1 decreases expression
multiple interactions		 ISO Bupivacaine results in decreased expression of SLC2A1 protein
HSPA12A protein inhibits the reaction [Bupivacaine results in decreased expression of SLC2A1 protein]		 CTD PMID:34793778 NCBI chr 5:132,717,196...132,745,416
Ensembl chr 5:132,717,196...132,745,416 		JBrowse link
G Slc2a4 solute carrier family 2 member 4 multiple interactions
decreases expression		 ISO HSPA12A protein inhibits the reaction [Bupivacaine results in decreased expression of SLC2A4 protein] CTD PMID:34793778 NCBI chr10:54,666,015...54,671,581
Ensembl chr10:54,666,015...54,671,565 		JBrowse link
G Slc6a2 solute carrier family 6 member 2 multiple interactions ISO Bupivacaine inhibits the reaction [[Desipramine results in decreased activity of SLC6A2 protein] which results in decreased abundance of Norepinephrine] CTD PMID:16725121 NCBI chr19:14,010,292...14,055,317
Ensembl chr19:14,010,386...14,050,357 		JBrowse link
G Tomm20 translocase of outer mitochondrial membrane 20 decreases expression
multiple interactions		 ISO Bupivacaine results in decreased expression of TOMM20 protein
HSPA12A protein inhibits the reaction [Bupivacaine results in decreased expression of TOMM20 protein]		 CTD PMID:34793778 NCBI chr19:54,925,197...54,935,188
Ensembl chr19:54,923,402...54,935,198 		JBrowse link
G Trpv1 transient receptor potential cation channel, subfamily V, member 1 increases activity
multiple interactions		 EXP Bupivacaine results in increased activity of TRPV1 protein
Bupivacaine affects the reaction [Capsaicin results in increased activity of TRPV1 protein]		 CTD PMID:15854744 PMID:18172555 NCBI chr10:57,851,428...57,876,513
Ensembl chr10:57,851,428...57,876,513 		JBrowse link
G Xrcc6 X-ray repair cross complementing 6 increases expression
multiple interactions		 ISO Bupivacaine results in increased expression of XRCC6 protein
8-dibenzothiophen-4-yl-2-morpholin-4-yl-chromen-4-one inhibits the reaction [[Glucose co-treated with Bupivacaine] results in increased expression of XRCC6 protein]; [Glucose co-treated with Bupivacaine] results in increased expression of XRCC6 protein; Glucose inhibits the reaction [Bupivacaine results in increased expression of XRCC6 protein]		 CTD PMID:31672611 NCBI chr 7:113,542,992...113,563,762
Ensembl chr 7:113,543,057...113,563,762 		JBrowse link
capivasertib term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Akt1 AKT serine/threonine kinase 1 increases phosphorylation ISO capivasertib results in increased phosphorylation of AKT1 protein CTD PMID:26853465 NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921 		JBrowse link
G Akt1s1 AKT1 substrate 1 decreases phosphorylation ISO capivasertib results in decreased phosphorylation of AKT1S1 protein CTD PMID:26853465 NCBI chr 1:95,333,186...95,339,678
Ensembl chr 1:95,332,898...95,339,677 		JBrowse link
G Bnip3 BCL2 interacting protein 3 multiple interactions ISO capivasertib affects the reaction [bafilomycin A1 results in increased expression of BNIP3 protein] CTD PMID:26853465 NCBI chr 1:193,708,164...193,725,348
Ensembl chr 1:193,708,167...193,725,359 		JBrowse link
G Casp3 caspase 3 multiple interactions ISO [capivasertib co-treated with Chloroquine] results in increased activity of CASP3 protein; CA 074 methyl ester inhibits the reaction [[capivasertib co-treated with Chloroquine] results in increased activity of CASP3 protein] CTD PMID:26853465 NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648 		JBrowse link
G Map1lc3b microtubule-associated protein 1 light chain 3 beta multiple interactions
increases expression		 ISO bafilomycin A1 promotes the reaction [capivasertib results in increased expression of MAP1LC3B protein modified form] CTD PMID:26853465 NCBI chr19:49,665,795...49,673,655
Ensembl chr19:49,665,791...49,677,690
Ensembl chr16:49,665,791...49,677,690 		JBrowse link
G Rpl18 ribosomal protein L18 multiple interactions ISO capivasertib inhibits the reaction [sodium arsenite results in increased expression of RPL18 mRNA]; capivasertib inhibits the reaction [sodium arsenite results in increased expression of RPL18 protein] CTD PMID:37061066 NCBI chr 1:96,188,811...96,191,452
Ensembl chr 1:96,188,112...96,191,452 		JBrowse link
G Rps21-ps1 ribosomal protein S21, pseudogene 1 multiple interactions ISO capivasertib inhibits the reaction [sodium arsenite results in increased expression of RPS21 mRNA]; capivasertib inhibits the reaction [sodium arsenite results in increased expression of RPS21 protein] CTD PMID:37061066 NCBI chr 5:153,387,133...153,387,476
Ensembl chr 5:153,387,176...153,387,427 		JBrowse link
G Rps6 ribosomal protein S6 decreases phosphorylation ISO capivasertib results in decreased phosphorylation of RPS6 protein CTD PMID:26853465 PMID:32397857 NCBI chr 5:101,371,716...101,374,576
Ensembl chr 5:101,371,136...101,374,602
Ensembl chr 5:101,371,136...101,374,602 		JBrowse link
G Sqstm1 sequestosome 1 affects expression ISO capivasertib affects the expression of SQSTM1 protein CTD PMID:26853465 NCBI chr10:34,525,517...34,536,670
Ensembl chr10:34,525,519...34,536,673 		JBrowse link
G Srebf1 sterol regulatory element binding transcription factor 1 decreases expression ISO capivasertib results in decreased expression of SREBF1 protein CTD PMID:26853465 NCBI chr10:45,007,637...45,029,650
Ensembl chr10:45,007,637...45,029,650 		JBrowse link
G Uba52 ubiquitin A-52 residue ribosomal protein fusion product 1 multiple interactions ISO capivasertib inhibits the reaction [sodium arsenite results in increased expression of UBA52 mRNA]; capivasertib inhibits the reaction [sodium arsenite results in increased expression of UBA52 protein] CTD PMID:37061066 NCBI chr16:18,918,614...18,920,807
Ensembl chr16:18,900,616...18,920,807 		JBrowse link
levobupivacaine term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Slc25a29 solute carrier family 25 member 29 multiple interactions
decreases activity		 EXP Emulsions inhibits the reaction [Levobupivacaine results in decreased activity of SLC25A29 protein] CTD PMID:35135371 NCBI chr 6:127,742,027...127,752,915
Ensembl chr 6:127,742,033...127,752,940 		JBrowse link
mepivacaine term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Kcne1 potassium voltage-gated channel subfamily E regulatory subunit 1 multiple interactions ISO Mepivacaine results in decreased activity of [KCNQ1 protein binds to KCNE1 protein] CTD PMID:16931984 NCBI chr11:31,580,951...31,594,116
Ensembl chr11:31,580,742...31,593,901 		JBrowse link
G Kcnq1 potassium voltage-gated channel subfamily Q member 1 decreases activity
multiple interactions		 ISO Mepivacaine results in decreased activity of KCNQ1 protein
Mepivacaine results in decreased activity of [KCNQ1 protein binds to KCNE1 protein]		 CTD PMID:16931984 NCBI chr 1:198,291,711...198,624,683
Ensembl chr 1:198,291,766...198,624,669 		JBrowse link
G Slc25a29 solute carrier family 25 member 29 decreases activity EXP Mepivacaine results in decreased activity of SLC25A29 protein CTD PMID:35135371 NCBI chr 6:127,742,027...127,752,915
Ensembl chr 6:127,742,033...127,752,940 		JBrowse link
G Trpv1 transient receptor potential cation channel, subfamily V, member 1 increases activity EXP Mepivacaine results in increased activity of TRPV1 protein CTD PMID:18172555 NCBI chr10:57,851,428...57,876,513
Ensembl chr10:57,851,428...57,876,513 		JBrowse link
ropivacaine term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Rac1 Rac family small GTPase 1 decreases activity ISO Ropivacaine decreases activity of RAC1 protein in esophageal carcinoma cells RGD PMID:29777701 RGD:155230817 NCBI chr12:11,037,028...11,057,251
Ensembl chr12:11,036,698...11,057,251 		JBrowse link
Term paths to the root
Path 1
Term Annotations click to browse term
  CHEBI ontology 19901
    chemical entity 19899
      atom 19899
        nonmetal atom 19822
          nitrogen atom 19006
            nitrogen molecular entity 19006
              organonitrogen compound 18859
                organonitrogen heterocyclic compound 18178
                  piperidines 7775
                    piperidinecarboxamide 83
                      (1-methylsulfonyl-4-piperidinyl)-(4-morpholinyl)methanone 0
                      (2S)-1-\{(2R)-2-[(8S,11S)-8-(2-amino-2-oxoethyl)-6,9-dioxo-2-oxa-7,10-diazabicyclo[11.2.2]heptadeca-1(15),13,16-trien-11-yl]-2-hydroxyethyl\}-N-tert-butylpiperidine-2-carboxamide 0
                      (2S)-N-tert-butylpiperidine-2-carboxamide 0
                      (3S)-1-[(E)-amino(imino)methyl]-N-(\{(2S)-1-[N-(2-naphthylsulfonyl)-L-seryl]pyrrolidin-2-yl\}methyl)piperidine-3-carboxamide 0
                      (S)-ropivacaine + 42
                      1-(1-methyl-4-nitro-1H-imidazol-5-yl)-4-piperidinecarboxamide 0
                      1-(2-chloro-4-pyrimidinyl)-4-piperidinecarboxamide 0
                      1-(4,6-dimethoxy-1,3,5-triazin-2-yl)-N-(thiophen-2-ylmethyl)-4-piperidinecarboxamide 0
                      1-(4-oxo-2-thieno[3,2-d][1,3]thiazinyl)-N-(phenylmethyl)-3-piperidinecarboxamide 0
                      1-(5-bromo-2-pyrimidinyl)-4-piperidinecarboxamide 0
                      1-(5-bromo-2-thiazolyl)-4-piperidinecarboxamide 0
                      1-[(3,5-dimethyl-1H-pyrazol-4-yl)sulfonyl]-N-(5-methyl-2-pyridinyl)-4-piperidinecarboxamide 0
                      1-[2-[3-(dimethylamino)phenyl]-4-pyrimidinyl]-4-piperidinecarboxamide 0
                      1-[4-(3,4,5-trimethoxyphenyl)-2-thiazolyl]-4-piperidinecarboxamide 0
                      1-[4-(3,4-dihydro-2H-1,5-benzodioxepin-7-yl)-2-thiazolyl]-4-piperidinecarboxamide 0
                      1-[4-(3-propan-2-yloxyphenyl)-2-thiazolyl]-4-piperidinecarboxamide 0
                      1-[4-(4-aminophenyl)-2-thiazolyl]-4-piperidinecarboxamide 0
                      1-[4-(4-bromophenyl)-2-thiazolyl]-4-piperidinecarboxamide 0
                      1-[4-(4-bromophenyl)-2-thiazolyl]-N-(3-phenylpropyl)-4-piperidinecarboxamide 0
                      1-[4-(4-bromophenyl)-2-thiazolyl]-N-(phenylmethyl)-4-piperidinecarboxamide 0
                      1-[4-(4-ethoxyphenyl)-2-thiazolyl]-4-piperidinecarboxamide 0
                      1-[4-(4-phenylmethoxyphenyl)-2-thiazolyl]-4-piperidinecarboxamide 0
                      1-[4-(4-propan-2-yloxyphenyl)-2-thiazolyl]-4-piperidinecarboxamide 0
                      1-[4-(4-tert-butylphenyl)-2-thiazolyl]-4-piperidinecarboxamide 0
                      1-[4-[4-(2-methylpropoxy)phenyl]-2-thiazolyl]-4-piperidinecarboxamide 0
                      1-[4-[4-(dimethylamino)phenyl]-2-thiazolyl]-4-piperidinecarboxamide 0
                      1-[4-[4-(methylthio)phenyl]-2-thiazolyl]-4-piperidinecarboxamide 0
                      1-[4-cyano-2-(2-furanyl)-5-oxazolyl]-4-piperidinecarboxamide 0
                      1-[5-[3-(dimethylamino)phenyl]-2-thiazolyl]-4-piperidinecarboxamide 0
                      1-[5-[4-(methylthio)phenyl]-2-thiazolyl]-4-piperidinecarboxamide 0
                      1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide + 42
                      2-[2-[[[1-(1H-imidazol-5-ylsulfonyl)-3-piperidinyl]-oxomethyl]amino]-4-thiazolyl]acetic acid ethyl ester 0
                      2-oxopiperidine-3-carbohydrazide 0
                      4-(2-iodacetamido)-TEMPO 0
                      4-Piperidine carboxamide 0
                      4-\{[5-chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino\}-N-ethylpiperidine-1-carboxamide 0
                      4-acetamido-TEMPO 0
                      Aspiperidine oxide 0
                      L-779976 0
                      LY-2090314 0
                      Methyl 4-(aminocarbonyl)-n-cyanotetrahydropyridine-1(2H)-carbimidothioate 0
                      N-(3-methylbutyl)-1-[(5-methyl-2-furanyl)methyl]-4-piperidinecarboxamide 0
                      N-(4-methylcyclohexyl)-1-(2-pyrazinyl)-4-piperidinecarboxamide 0
                      N-(5-\{[(5-tert-butyl-1,3-oxazol-2-yl)methyl]sulfanyl\}-1,3-thiazol-2-yl)piperidine-4-carboxamide 0
                      N-[(1R)-2-\{(2S)-2-[(3-carbamimidamidopropyl)carbamoyl]piperidin-1-yl\}-1-(cyclohexylmethyl)-2-oxoethyl]glycine 0
                      N-[(3-methoxyphenyl)methyl]-1-[(6-methyl-2,4-dioxo-1H-pyrimidin-5-yl)sulfonyl]-3-piperidinecarboxamide 0
                      N-[2-(3,4-diethoxyphenyl)ethyl]-1-[6-(4-morpholinyl)-3-pyridazinyl]-4-piperidinecarboxamide 0
                      N-[3-(1-azepanyl)propyl]-1-ethylsulfonyl-4-piperidinecarboxamide 0
                      N-[4-(4-methylphenyl)-2-thiazolyl]-1-thiophen-2-ylsulfonyl-4-piperidinecarboxamide 0
                      N-[6,6-dimethyl-5-[(1-methyl-4-piperidinyl)-oxomethyl]-1,4-dihydropyrrolo[3,4-c]pyrazol-3-yl]-3-methylbutanamide 0
                      N-tert-butyl-1-[[5-[2-(2-ethoxyphenyl)ethenyl]-3-methyl-1,2-oxazol-4-yl]sulfonyl]piperidine-4-carboxamide 0
                      [1-[4-(4-bromophenyl)-2-thiazolyl]-4-piperidinyl]-(1-piperazinyl)methanone 0
                      capivasertib 11
                      gartisertib 0
                      mepivacaine + 4
                      mepivacaine hydrochloride 0
                      nipecotamide + 0
                      rac5c 0
                      ropivacaine + 43
                      zavegepant 0
Path 2
Term Annotations click to browse term
  CHEBI ontology 19901
    subatomic particle 19899
      composite particle 19899
        hadron 19899
          baryon 19899
            nucleon 19899
              atomic nucleus 19899
                atom 19899
                  main group element atom 19838
                    p-block element atom 19838
                      carbon group element atom 19778
                        carbon atom 19775
                          organic molecular entity 19775
                            heteroorganic entity 19534
                              organochalcogen compound 19295
                                organooxygen compound 19211
                                  carbon oxoacid 18679
                                    carboxylic acid 18676
                                      carboacyl group 17718
                                        univalent carboacyl group 17718
                                          carbamoyl group 17569
                                            carboxamide 17569
                                              monocarboxylic acid amide 15745
                                                piperidinecarboxamide 83
                                                  (1-methylsulfonyl-4-piperidinyl)-(4-morpholinyl)methanone 0
                                                  (2S)-1-\{(2R)-2-[(8S,11S)-8-(2-amino-2-oxoethyl)-6,9-dioxo-2-oxa-7,10-diazabicyclo[11.2.2]heptadeca-1(15),13,16-trien-11-yl]-2-hydroxyethyl\}-N-tert-butylpiperidine-2-carboxamide 0
                                                  (2S)-N-tert-butylpiperidine-2-carboxamide 0
                                                  (3S)-1-[(E)-amino(imino)methyl]-N-(\{(2S)-1-[N-(2-naphthylsulfonyl)-L-seryl]pyrrolidin-2-yl\}methyl)piperidine-3-carboxamide 0
                                                  (S)-ropivacaine + 42
                                                  1-(1-methyl-4-nitro-1H-imidazol-5-yl)-4-piperidinecarboxamide 0
                                                  1-(2-chloro-4-pyrimidinyl)-4-piperidinecarboxamide 0
                                                  1-(4,6-dimethoxy-1,3,5-triazin-2-yl)-N-(thiophen-2-ylmethyl)-4-piperidinecarboxamide 0
                                                  1-(4-oxo-2-thieno[3,2-d][1,3]thiazinyl)-N-(phenylmethyl)-3-piperidinecarboxamide 0
                                                  1-(5-bromo-2-pyrimidinyl)-4-piperidinecarboxamide 0
                                                  1-(5-bromo-2-thiazolyl)-4-piperidinecarboxamide 0
                                                  1-[(3,5-dimethyl-1H-pyrazol-4-yl)sulfonyl]-N-(5-methyl-2-pyridinyl)-4-piperidinecarboxamide 0
                                                  1-[2-[3-(dimethylamino)phenyl]-4-pyrimidinyl]-4-piperidinecarboxamide 0
                                                  1-[4-(3,4,5-trimethoxyphenyl)-2-thiazolyl]-4-piperidinecarboxamide 0
                                                  1-[4-(3,4-dihydro-2H-1,5-benzodioxepin-7-yl)-2-thiazolyl]-4-piperidinecarboxamide 0
                                                  1-[4-(3-propan-2-yloxyphenyl)-2-thiazolyl]-4-piperidinecarboxamide 0
                                                  1-[4-(4-aminophenyl)-2-thiazolyl]-4-piperidinecarboxamide 0
                                                  1-[4-(4-bromophenyl)-2-thiazolyl]-4-piperidinecarboxamide 0
                                                  1-[4-(4-bromophenyl)-2-thiazolyl]-N-(3-phenylpropyl)-4-piperidinecarboxamide 0
                                                  1-[4-(4-bromophenyl)-2-thiazolyl]-N-(phenylmethyl)-4-piperidinecarboxamide 0
                                                  1-[4-(4-ethoxyphenyl)-2-thiazolyl]-4-piperidinecarboxamide 0
                                                  1-[4-(4-phenylmethoxyphenyl)-2-thiazolyl]-4-piperidinecarboxamide 0
                                                  1-[4-(4-propan-2-yloxyphenyl)-2-thiazolyl]-4-piperidinecarboxamide 0
                                                  1-[4-(4-tert-butylphenyl)-2-thiazolyl]-4-piperidinecarboxamide 0
                                                  1-[4-[4-(2-methylpropoxy)phenyl]-2-thiazolyl]-4-piperidinecarboxamide 0
                                                  1-[4-[4-(dimethylamino)phenyl]-2-thiazolyl]-4-piperidinecarboxamide 0
                                                  1-[4-[4-(methylthio)phenyl]-2-thiazolyl]-4-piperidinecarboxamide 0
                                                  1-[4-cyano-2-(2-furanyl)-5-oxazolyl]-4-piperidinecarboxamide 0
                                                  1-[5-[3-(dimethylamino)phenyl]-2-thiazolyl]-4-piperidinecarboxamide 0
                                                  1-[5-[4-(methylthio)phenyl]-2-thiazolyl]-4-piperidinecarboxamide 0
                                                  1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide + 42
                                                  2-[2-[[[1-(1H-imidazol-5-ylsulfonyl)-3-piperidinyl]-oxomethyl]amino]-4-thiazolyl]acetic acid ethyl ester 0
                                                  2-oxopiperidine-3-carbohydrazide 0
                                                  4-(2-iodacetamido)-TEMPO 0
                                                  4-Piperidine carboxamide 0
                                                  4-\{[5-chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino\}-N-ethylpiperidine-1-carboxamide 0
                                                  4-acetamido-TEMPO 0
                                                  Aspiperidine oxide 0
                                                  L-779976 0
                                                  LY-2090314 0
                                                  Methyl 4-(aminocarbonyl)-n-cyanotetrahydropyridine-1(2H)-carbimidothioate 0
                                                  N-(3-methylbutyl)-1-[(5-methyl-2-furanyl)methyl]-4-piperidinecarboxamide 0
                                                  N-(4-methylcyclohexyl)-1-(2-pyrazinyl)-4-piperidinecarboxamide 0
                                                  N-(5-\{[(5-tert-butyl-1,3-oxazol-2-yl)methyl]sulfanyl\}-1,3-thiazol-2-yl)piperidine-4-carboxamide 0
                                                  N-[(1R)-2-\{(2S)-2-[(3-carbamimidamidopropyl)carbamoyl]piperidin-1-yl\}-1-(cyclohexylmethyl)-2-oxoethyl]glycine 0
                                                  N-[(3-methoxyphenyl)methyl]-1-[(6-methyl-2,4-dioxo-1H-pyrimidin-5-yl)sulfonyl]-3-piperidinecarboxamide 0
                                                  N-[2-(3,4-diethoxyphenyl)ethyl]-1-[6-(4-morpholinyl)-3-pyridazinyl]-4-piperidinecarboxamide 0
                                                  N-[3-(1-azepanyl)propyl]-1-ethylsulfonyl-4-piperidinecarboxamide 0
                                                  N-[4-(4-methylphenyl)-2-thiazolyl]-1-thiophen-2-ylsulfonyl-4-piperidinecarboxamide 0
                                                  N-[6,6-dimethyl-5-[(1-methyl-4-piperidinyl)-oxomethyl]-1,4-dihydropyrrolo[3,4-c]pyrazol-3-yl]-3-methylbutanamide 0
                                                  N-tert-butyl-1-[[5-[2-(2-ethoxyphenyl)ethenyl]-3-methyl-1,2-oxazol-4-yl]sulfonyl]piperidine-4-carboxamide 0
                                                  [1-[4-(4-bromophenyl)-2-thiazolyl]-4-piperidinyl]-(1-piperazinyl)methanone 0
                                                  capivasertib 11
                                                  gartisertib 0
                                                  mepivacaine + 4
                                                  mepivacaine hydrochloride 0
                                                  nipecotamide + 0
                                                  rac5c 0
                                                  ropivacaine + 43
                                                  zavegepant 0
paths to the root